1 Department of Medical Oncology, 2 Department of Internal Medicine, 3 Department of Urology, 4 Department of Radiology, 5 Department of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
*E-mail: stakahas@jfcr.or.jp
Malignant pheochromocytomas are rare, accounting for 10% of all cases of pheochromocytoma. The prognosis is poor because of local recurrence or widespread metastasis [1]. To date, there has been no established chemotherapy for malignant pheochromocytoma. A conventional CVD regimen (consisting of cyclophosphamide, vincristine and dacarbazine) may reduce tumors, but remission is short [2]. Thus, attempts to devise other regimens are warranted in order to obtain a better outcome.
We report a 50-year-old Japanese male who had rapidly progressive malignant pheochromocytoma and was successfully treated with an ACVD regimen, anthracyclines plus CVD. The patient was diagnosed with left adrenal pheochromocytoma (4 x 3 cm) with increased catecholamine (CA) excretion levels and underwent adrenectomy in August 1990. He had become asymptomatic and CA excretion level dropped to normal after the surgery. Six years later, he presented with lower back pain, soaking sweats and right inguinal lymphadenopathy. CAs and their metabolites were elevated (Table 1). A CT (computed tomography) scan showed enlarged lymph nodes in the pelvic and para-aortic region. Biopsy specimens of the inguinal lymph node revealed relapse of the pheochromocytoma. Subsequently, the right inguinal lymph node enlarged from 2 to 10 cm in 2 weeks, and the back pain was aggravated.
|
Considering their neural crest origin and biological similarities, the chemotherapeutic regimens for neuroblastoma could be promising candidates for malignant pheochromocytoma. The CVD regimen was based on the treatment for advanced neuroblastoma. This regimen has been reported to produce good responses in malignant pheochromocytoma, but the median duration of remission is 21 months [2]. For aggressive neuroblastoma, a combination chemotherapeutic regimen of cyclophosphamide, vincristine, dacarbazine and doxorubicin (CYVADIC) has been suggested to be more effective than doxorubicin alone or combination therapy without doxorubicin (CYVDIC) [3]. We achieved long-lasting complete remission using a ACVD regimen in a case with rapidly progressive disease.
To our knowledge, this is the first report of an anthracycline-containing combination chemotherapy for metastasized malignant pheochromocytoma. The ACVD regimen might be a feasible combination chemotherapy, with monitoring of the cardiovascular system; furthermore, it might improve response rates and lengthen disease-free survival.
M. Nakane1, S. Takahashi1*, I. Sekine2, I. Fukui3, M. Koizumi4, K. Kage2, Y. Ito1, K. Aiba1, N. Horikoshi1, K. Hatake1, Y. Ishikawa5 & E. Ogata2
1Department of Medical Oncology, 2Department of Internal Medicine, 3Department of Urology, 4Department of Radiology, 5Department of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan (*E-mail: stakahas@jfcr.or.jp)
References
1. van Heerden JA, Sheps SG, Hamberger B et al. Pheochromocytoma: current status and changing trends. Surgery 1982; 91: 367373.[ISI][Medline]
2. Averbuch SD, Steakley CS, Young RC et al. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 1988; 109: 267273.[ISI][Medline]
3. Dosik GM, Rodriguez V, Benjamin RS, Bodey GP. Neuroblastoma in the adult: effective combination chemotherapy. Cancer 1978; 41: 5663.[ISI][Medline]